Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025

Future directions in the management of warm autoimmune hemolytic anemia.

View Full Paper
Ask AI
Bookmark
Share

Authors

HWHideho Wada

Discussion

Loading...

Member takes

Overview

Observational findings reveal various treatment options for warm autoimmune hemolytic anemia, suggesting new therapeutic directions.

Key Points

  • New therapies for warm autoimmune hemolytic anemia include FcRn inhibitors and SyK inhibitors, indicating potential advancements in treatment options.
  • Research shows that Fostamatinib resulted in higher sustained hemoglobin responses compared to placebo in a phase 3 trial.
  • Corticosteroids remain the first-line therapy, while rituximab and splenectomy serve as effective second-line treatments.
  • There’s currently no consensus on therapy for patients with warm autoimmune hemolytic anemia refractory to second-line options.

Cite This Study

Hideho Wada (2025) studied this question.

synapsesocial.com/papers/68c23c20b210217d64787d5dhttps://doi.org/10.11406/rinketsu.66.766
View Full Paper
Ask AI
Bookmark
Share